{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,19]],"date-time":"2026-05-19T05:33:19Z","timestamp":1779168799747,"version":"3.51.4"},"reference-count":28,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2019,8,1]],"date-time":"2019-08-01T00:00:00Z","timestamp":1564617600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,8,1]],"date-time":"2019-08-01T00:00:00Z","timestamp":1564617600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100003593","name":"Conselho Nacional de Desenvolvimento Cient\u00edfico e Tecnol\u00f3gico","doi-asserted-by":"publisher","award":["302622\/2015-2"],"award-info":[{"award-number":["302622\/2015-2"]}],"id":[{"id":"10.13039\/501100003593","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002322","name":"Coordena\u00e7\u00e3o de Aperfei\u00e7oamento de Pessoal de N\u00edvel Superior","doi-asserted-by":"publisher","award":["14679\/13-2"],"award-info":[{"award-number":["14679\/13-2"]}],"id":[{"id":"10.13039\/501100002322","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinical-genitourinary-cancer.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Genitourinary Cancer"],"published-print":{"date-parts":[[2019,8]]},"DOI":"10.1016\/j.clgc.2019.04.003","type":"journal-article","created":{"date-parts":[[2019,4,16]],"date-time":"2019-04-16T11:53:14Z","timestamp":1555415594000},"page":"e779-e783","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":9,"title":["Moreau Strain Bacillus Calmette-Gu\u00e9rin Low Versus Standard Dose in the Treatment of High-Grade T1 Bladder Cancer: A Retrospective Observational Cohort Study"],"prefix":"10.1016","volume":"17","author":[{"given":"Bruno D.B.","family":"Carneiro","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Brunno C.F.","family":"Sanches","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Danilo L.","family":"Andrade","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Brunno R.I.","family":"Voris","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2092-414X","authenticated-orcid":false,"given":"Leonardo O.","family":"Reis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.clgc.2019.04.003_bib1","first-page":"7","article-title":"Cancer statistics, 2016","volume":"66","author":"Siegel","year":"2016","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.clgc.2019.04.003_bib2","first-page":"1964","article-title":"Intravesical bacillus Calmette-Gu\u00e9rin reduces the risk of progression in patients with superficial bladder cancer: a meta-analysis of the published results of randomized clinical trials","volume":"168","author":"Sylvester","year":"2002","journal-title":"J\u00a0Urol"},{"key":"10.1016\/j.clgc.2019.04.003_bib3","first-page":"180","article-title":"Intracavitary bacillus Calmette-Gu\u00e9rin in the treatment of superficial bladder tumors","volume":"116","author":"Morales","year":"1976","journal-title":"J\u00a0Urol"},{"issue":"suppl 5","key":"10.1016\/j.clgc.2019.04.003_bib4","doi-asserted-by":"crossref","first-page":"S99","DOI":"10.1016\/S1166-7087(08)72485-0","article-title":"[Bacillus of Calmette-Gu\u00e9rin immunotherapy: which protocol?]","volume":"18","author":"Saint","year":"2008","journal-title":"Prog Urol"},{"key":"10.1016\/j.clgc.2019.04.003_bib5","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1159\/000019664","article-title":"Low-dose BCG instillations in the treatment of stage T1 grade 3 bladder tumours: recurrence, progression and success","volume":"34","author":"Lebret","year":"1998","journal-title":"Eur Urol"},{"key":"10.1016\/j.clgc.2019.04.003_bib6","first-page":"68","article-title":"Low dose bacillus Calmette-Gu\u00e9rin for carcinoma in situ of the bladder: long-term results","volume":"163","author":"Losa","year":"2000","journal-title":"J\u00a0Urol"},{"key":"10.1016\/j.clgc.2019.04.003_bib7","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1097\/MOU.0000000000000544","article-title":"What to do during bacillus Calmette-Gu\u00e9rin shortage? Valid strategies based on evidence","volume":"28","author":"Abufaraj","year":"2018","journal-title":"Curr Opin Urol"},{"key":"10.1016\/j.clgc.2019.04.003_bib8","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1016\/j.urolonc.2016.05.033","article-title":"The efficacy of BCG TICE and BCG Connaught in a cohort of 2,099 patients with T1G3 non\u2013muscle-invasive bladder cancer","volume":"34","author":"Witjes","year":"2016","journal-title":"Urol Oncol"},{"key":"10.1016\/j.clgc.2019.04.003_bib9","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1046\/j.0919-8172.2003.00607.x","article-title":"Sufficient prophylactic efficacy with minor adverse effects by intravesical instillation of low-dose bacillus Calmette-Gu\u00e9rin for superficial bladder cancer recurrence","volume":"10","author":"Irie","year":"2003","journal-title":"Int J Urol"},{"key":"10.1016\/j.clgc.2019.04.003_bib10","series-title":"TNM Classification of Malignant Tumours","author":"Sobin","year":"2009"},{"key":"10.1016\/j.clgc.2019.04.003_bib11","series-title":"The World Health Organization Classification of Tumors of the Urinary System and Male Genital System","author":"Eble","year":"2004"},{"key":"10.1016\/j.clgc.2019.04.003_bib12","first-page":"25","article-title":"Multicenter analysis of the oncological positivity on restaging resection (re-TURBT) of urothelial non\u2013muscle-invasive bladder cancer","volume":"2","author":"Ferreira","year":"2017","journal-title":"ARC J Urol"},{"key":"10.1016\/j.clgc.2019.04.003_bib13","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1016\/0021-9681(87)90171-8","article-title":"A\u00a0new method of classifying prognostic comorbidity in longitudinal studies: development and validation","volume":"40","author":"Charlson","year":"1987","journal-title":"J\u00a0Chron Dis"},{"key":"10.1016\/j.clgc.2019.04.003_bib14","author":"Datovo"},{"key":"10.1016\/j.clgc.2019.04.003_bib15","first-page":"503","article-title":"Efficacy of bacillus Calmette-Gu\u00e9rin strains for treatment of nonmuscle invasive bladder cancer: a systematic review and network meta-analysis","volume":"198","author":"Boehm","year":"2017","journal-title":"J\u00a0Urol"},{"key":"10.1016\/j.clgc.2019.04.003_bib16","first-page":"711","article-title":"Connaught and Russian strains showed the highest direct antitumor effects of different bacillus Calmette-Gu\u00e9rin substrains","volume":"189","author":"Secanella-Fandos","year":"2013","journal-title":"J\u00a0Urol"},{"key":"10.1016\/j.clgc.2019.04.003_bib17","first-page":"426","article-title":"Treatment of patients with superficial bladder cancer stratified by risk groups treated with lyophilized Moreau\u2013Rio de Janeiro BCG strain","volume":"28","author":"Fonseca","year":"2002","journal-title":"Int Braz J Urol"},{"key":"10.1016\/j.clgc.2019.04.003_bib18","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1159\/000440701","article-title":"The Moreau Strain of bacillus Calmette-Gu\u00e9rin (BCG) for high-risk non\u2013muscle invasive bladder cancer: an alternative during worldwide BCG Shortage?","volume":"96","author":"Hofbauer","year":"2016","journal-title":"Urol Int"},{"key":"10.1016\/j.clgc.2019.04.003_bib19","first-page":"1","article-title":"Are there differences in toxicity and efficacy between various bacillus Calmette-Gu\u00e9rin strains in bladder cancer patients? Analysis of 844 patients","volume":"18","author":"Krajewski","year":"2018","journal-title":"Urol Int"},{"key":"10.1016\/j.clgc.2019.04.003_bib20","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1016\/j.eururo.2012.10.039","article-title":"Final results of an EORTC-GU cancers group randomized study of maintenance bacillus Calmette-Gu\u00e9rin in intermediate- and high-risk Ta, T1 papillary carcinoma of the urinary bladder: one-third dose versus full dose and 1 year versus 3 years of maintenance","volume":"63","author":"Oddens","year":"2013","journal-title":"Eur Urol"},{"key":"10.1016\/j.clgc.2019.04.003_bib21","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1016\/j.eururo.2015.02.040","article-title":"Maintenance therapy with 3-monthly bacillus Calmette-Gu\u00e9rin for 3 years is not superior to standard induction therapy in high-risk non\u2013muscle-invasive urothelial bladder carcinoma: final results of randomised CUETO study 98013","volume":"68","author":"Mart\u00ednez-Pi\u00f1eiro","year":"2015","journal-title":"Eur Urol"},{"key":"10.1016\/j.clgc.2019.04.003_bib22","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1590\/S1677-5538.IBJU.2015.0122","article-title":"Are we following the guidelines on non-muscle invasive bladder cancer?","volume":"42","author":"Reis","year":"2016","journal-title":"Int Braz J Urol"},{"key":"10.1016\/j.clgc.2019.04.003_bib23","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1016\/S0302-2838(03)00357-9","article-title":"Maintenance bacillus Calmette-Gu\u00e9rin for Ta T1 bladder tumors is not associated with increased toxicity: results from a European Organization for Research and Treatment of Cancer Genito-Urinary Group phase III trial","volume":"44","author":"van der Meijden","year":"2003","journal-title":"Eur Urol"},{"key":"10.1016\/j.clgc.2019.04.003_bib24","first-page":"298","article-title":"Effective dose and adverse effects of maintenance bacillus Calmette-Gu\u00e9rin in intermediate and high risk non\u2013muscle invasive bladder cancer: a meta-analysis of randomized clinical trial","volume":"46","author":"Astram","year":"2014","journal-title":"Acta Med Indones"},{"key":"10.1016\/j.clgc.2019.04.003_bib26","doi-asserted-by":"crossref","first-page":"e2176","DOI":"10.1097\/MD.0000000000002176","article-title":"Low-dose versus standard dose of bacillus Calmette-Gu\u00e9rin in the treatment of nonmuscle invasive bladder cancer: a systematic review and meta-analysis","volume":"94","author":"Zeng","year":"2015","journal-title":"Medicine (Baltimore)"},{"key":"10.1016\/j.clgc.2019.04.003_bib27","doi-asserted-by":"crossref","first-page":"3970","DOI":"10.3760\/cma.j.issn.0366-6999.20141045","article-title":"Reduced dose of bacillus Calmette-Gu\u00e9rin versus full dose of bacillus Calmette-Gu\u00e9rin for non\u2013muscle-invasive bladder cancer after transurethral resection bladder tumor: a meta-analysis of randomized controlled trials","volume":"127","author":"Qin","year":"2014","journal-title":"Chin Med J (Engl)"},{"key":"10.1016\/j.clgc.2019.04.003_bib28","first-page":"1903","article-title":"The dose\u2013response relationship of bacillus Calmette-Gu\u00e9rin and urothelial carcinoma cell biology","volume":"195","author":"Shah","year":"2016","journal-title":"J\u00a0Urol"},{"key":"10.1016\/j.clgc.2019.04.003_bib29","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/j.urology.2018.04.039","article-title":"Patient compliance with maintenance intravesical therapy for nonmuscle invasive bladder cancer","volume":"118","author":"Tapiero","year":"2018","journal-title":"Urology"}],"container-title":["Clinical Genitourinary Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1558767319301296?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1558767319301296?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,12]],"date-time":"2026-05-12T20:39:50Z","timestamp":1778618390000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1558767319301296"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,8]]},"references-count":28,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2019,8]]}},"alternative-id":["S1558767319301296"],"URL":"https:\/\/doi.org\/10.1016\/j.clgc.2019.04.003","relation":{},"ISSN":["1558-7673"],"issn-type":[{"value":"1558-7673","type":"print"}],"subject":[],"published":{"date-parts":[[2019,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Moreau Strain Bacillus Calmette-Gu\u00e9rin Low Versus Standard Dose in the Treatment of High-Grade T1 Bladder Cancer: A Retrospective Observational Cohort Study","name":"articletitle","label":"Article Title"},{"value":"Clinical Genitourinary Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clgc.2019.04.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}